Benitec Biopharma Inc.

Benitec Biopharma Inc. is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines, headquartered in Hayward, California. The company operates in the biopharmaceutical industry, which is characterized by intense and dynamic competition to develop new technologies and proprietary therapies. The industry includes larger and better-funded pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as academic institutions and governmental agencies. The company's proprietary technology platform, DNA-directed RNA interference (ddRNAi) and "silence and replace," is designed to produce permanent silencing of disease-causing genes and simultaneously replace mutant genes with functional genes. No product candidates utilizing ddRNAi or silence and replace technology have been approved for commercial sale, and the company is early in its product development efforts, with its lead candidate, BB-301, in early clinical development.

The company faces potential competition from many sources, including larger and better-funded pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as academic institutions and governmental agencies. The company is not aware of any companies developing a gene therapy or gene silencing approach for OPMD. The company believes its proprietary technology and scientific expertise in gene silencing using ddRNAi provide competitive advantages. The company's product candidates, if approved, would compete on the basis of efficacy, safety, convenience of administration and delivery, price, and the availability of reimbursement. The company expects its therapeutic products, if approved, to be priced at a significant premium over competitive products, and its ability to compete may be affected by insurers or other third-party payers seeking to encourage the use of competitive products.

The company generates revenue through the development and potential commercialization of its product candidates, primarily BB-301, an AAV-based gene therapy for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD). The company has never generated any revenue from product sales and may never be profitable. The company's strategy is to discover, develop, and commercialize treatments leveraging ddRNAi and silence and replace technology. For selected product candidates, the company may collaborate with large biopharmaceutical companies to co-develop and commercialize products. For indications outside its immediate focus, the company may out-license applications of its technology. The company's cash and cash equivalents will be deployed for the advancement of BB-301, continued development of other product candidates, general corporate purposes, and strategic growth opportunities.

BB-301 is the company's lead investigational gene therapy agent, designed to correct the genetic defect underlying OPMD following a single localized administration. BB-301 is composed of a modified AAV serotype 9 (AAV9) capsid that expresses a bifunctional construct under the control of a single muscle-specific Spc5-12 promoter, achieving co-expression of both the codon-optimized PABPN1 mRNA and two shmiR molecules directed against wild type and mutant PABPN1. BB-301 has been granted Orphan Drug Designation and Fast Track Designation in the United States and Orphan Drug Designation in the European Union. The company believes the commercial opportunity for a safe and efficacious therapeutic agent in OPMD exceeds $1 billion ¹ over the course of the commercial life of the product. No therapeutic agents are approved for the treatment of OPMD, and there are no surgical interventions available that modify the natural history of the disease.

The company's pipeline includes BB-301 for OPMD, which is in a Phase 1b/2a clinical trial (NCT06185673). The IND application for BB-301 was approved by the FDA in June 2023, and the first study subject was safely treated in November 2023. All Cohort 1 subjects have safely completed the 12-month post-treatment follow-up period, and the company has treated three subjects in Cohort 2. A Type C meeting was held with the FDA in the third quarter of 2026 to discuss the BB-301 pivotal study design. The company's intellectual property portfolio includes four active patent families relating to shRNA and shmiRs targeting PABPN1, "silence and replace" therapeutics, and delivery methods and devices for BB-301, as well as a patent family for an AAV with a modified phospholipase domain. The company does not own or operate manufacturing facilities and relies on third-party contract manufacturing organizations for the production of its product candidates.

As of June 30, 2026, the company had 24 full-time employees, with 17 engaged in research and development activities and seven in finance, legal, human resources, facilities, and general management. The company has incurred significant losses since inception, with accumulated losses of $273.7 million ² as of June 30, 2026. The company has financed its operations primarily through the issuance of equity securities, research and development grants from the Australian government, and payments from collaboration partners. The company estimates that its cash and cash equivalents will be sufficient to fund operations for at least the next twelve months after the filing date of the Annual Report. The company will require additional financing to progress its product candidates through future inflection points.

The company has never generated any revenue from product sales and expects to incur significant operating losses for the foreseeable future due to the cost of research and development, preclinical studies, clinical trials, and the regulatory approval process. The company's net losses may fluctuate significantly from quarter to quarter and year to year. The company's ability to achieve profitability depends on its ability to successfully complete development, obtain regulatory approvals, manufacture sufficient supply, establish sales and marketing capabilities, and commercialize any approved products. The company's expenses are expected to increase substantially as it continues research and development, expands clinical studies, seeks regulatory approvals, develops manufacturing processes, and maintains its intellectual property portfolio.

The company estimates that its cash and cash equivalents will be sufficient to fund operations for at least the next twelve months after the date the Annual Report is filed. The company expects to incur significant operating losses for the foreseeable future and anticipates that expenses will increase substantially as it continues development activities.

The primary growth vector for the company is the advancement of BB-301 for the treatment of OPMD-derived dysphagia. The company is conducting a natural history lead-in study and a Phase 1b/2a BB-301 treatment study. The company held a Type C meeting with the FDA in the third quarter of 2026 to discuss the BB-301 pivotal study design. The company believes the commercial opportunity for a safe and efficacious therapeutic agent in OPMD exceeds $1 billion ³ over the course of the commercial life of the product. The company is also exploring long-term manufacturing alliances with potential partners to support future commercialization efforts.

The company's growth strategy includes potentially collaborating with large biopharmaceutical companies to co-develop and commercialize its ddRNAi-based and silence and replace-based products. For specific clinical indications outside its immediate focus, the company plans to out-license applications of its technology to facilitate the development of differentiated therapeutics. The company's intellectual property portfolio, including patents covering BB-301 and its delivery methods, is a key strategic asset for maintaining exclusivity and competitive positioning.

The company's cost structure is primarily driven by research and development expenses, including clinical and preclinical development activities, and general and administrative expenses. The company expects its expenses to increase substantially as it continues research and development, expands clinical studies, seeks regulatory approvals, and develops manufacturing processes. The company does not provide specific margin or cost outlook figures in the filing.

The company does not own or operate manufacturing facilities and relies entirely on third-party contract manufacturing organizations for the production of its product candidates. The company is exploring long-term manufacturing alliances with potential partners to produce materials at reasonable scale and cost of goods to support future commercialization efforts. The company does not have a long-term agreement with any third-party manufacturer but plans to establish such a relationship. The company's manufacturing is subject to extensive regulations, including cGMP requirements.

The company plans to deploy its cash and cash equivalents for the advancement of BB-301, continued development of other product candidates, general corporate purposes, and strategic growth opportunities. The company does not provide specific R&D spending levels, capital expenditure plans, or share repurchase authorization amounts in the filing. The company has never generated any revenue from product sales and may need to obtain additional funding to continue operations.

The company faces significant headwinds, including the risk that its product candidates may not receive regulatory approval, the uncertainty of clinical trial outcomes, and the potential for adverse events associated with gene therapy. The company also faces competition from entities with substantially greater financial, technical, and human resources. The company may be unable to obtain additional funding on acceptable terms, which could negatively impact its ability to continue as a going concern. The company's ability to enroll patients in clinical trials may be affected by the rarity of OPMD and the availability of competing therapies.

The company is subject to extensive government regulation, and changes in regulatory requirements or policies could delay or prevent the development and commercialization of its product candidates. The company faces risks related to the FDA's limited experience with ddRNAi-based therapeutics, which makes it difficult to predict the time and cost of obtaining regulatory approvals. The company also faces risks related to the potential for adverse immune responses to AAV vectors, which could limit the effectiveness of its product candidates. The company's reliance on third-party manufacturers and suppliers exposes it to risks of supply interruptions and manufacturing complexity.

The company has incurred significant losses since inception, with accumulated losses of $273.7 million ⁴ as of June 30, 2026, and expects to continue incurring losses for the foreseeable future. The company has never generated any revenue from product sales and may never be profitable. The company will need to raise additional funding, which may not be available on acceptable terms, and failure to obtain capital could negatively impact its ability to continue as a going concern. The company's product candidates are based on ddRNAi and silence and replace technology, and no product candidates utilizing these technologies have been approved for commercial sale. The company is early in its product development efforts, and its lead candidate, BB-301, is in early clinical development. The company faces competition from entities with substantially greater financial, technical, and human resources. The company relies on third parties for the manufacture and supply of its product candidates, and any disruption in these relationships could adversely affect its ability to develop and commercialize its products. The company's product candidates may cause undesirable side effects, including adverse immunological responses to AAV vectors, which could delay or prevent regulatory approval. The company's ability to enroll patients in clinical trials may be affected by the rarity of OPMD and the availability of competing therapies. The company is subject to extensive government regulation, and changes in regulatory requirements or policies could delay or prevent the development and commercialization of its product candidates.

Management's message emphasizes the company's focus on advancing BB-301, its lead silence and replace-based therapeutic for OPMD, and the progress made in the Phase 1b/2a clinical trial. The company has treated three subjects in Cohort 2, and all Cohort 1 subjects have safely completed the 12-month post-treatment follow-up period. Management highlights the potential of the silence and replace mechanism to restore normative physiology and improve treatment outcomes, and the company believes the commercial opportunity for BB-301 exceeds $1 billion ⁵. The company's strategic priorities include progressing BB-301 through clinical development, continuing development of other product candidates, and securing additional financing to fund operations. Management acknowledges the company will require additional financing to progress its product candidates through future inflection points.